We have created a technology platform that allows physicians the opportunity to integrate autologous PRP (Platelet-rich Plasma) and BMCC (Bone Marrow Cell Concentrate) biologic preparations into their practice.
Learn More
The use of a patient’s own biologic preparation complements the natural healing process present in patients but is dependent on a variety of components.
Learn More
Numerous reports on potential applications for PRP and BMCC suggest that autologous PRP and BMCC preparations are considered to support a patient’s natural healing processes.
Learn More
Founder and Chief Executive Officer
Greyledge operations are currently being led by company Founder and CEO – David Karli. He is responsible for all aspects of company development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to regenerative medicine.
Vice President Research and Regulatory Affairs
Dr. Sand recently joined the company to support on-going commercialization efforts, as well as initiate an active research program to advance the company’s technology platform.
